- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Ruxolitinib in Glucocorticoid Refractory Chronic Graft versus Host Disease ; volume:42 ; number:06 ; year:2021 ; pages:582-583
Indian journal of medical & paediatric oncology ; 42, Heft 06 (2021), 582-583
- Beteiligte Personen und Organisationen
-
Sharma, Aparna
Sharma, Vibhor
- DOI
-
10.1055/s-0041-1740950
- URN
-
urn:nbn:de:101:1-2022021710515179151027
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:38 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sharma, Aparna
- Sharma, Vibhor
Ähnliche Objekte (12)
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease: A Giant Leap-To Start with Baby Steps
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
Role of microglia in neurological side effects of cancer immunotherapies and of ruxolitinib in steroid-refractory gastrointestinal graft versus host disease
Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis
Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease: A Giant Leap-To Start with Baby Steps
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
Role of microglia in neurological side effects of cancer immunotherapies and of ruxolitinib in steroid-refractory gastrointestinal graft versus host disease
Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis
Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease: A Giant Leap-To Start with Baby Steps
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
Role of microglia in neurological side effects of cancer immunotherapies and of ruxolitinib in steroid-refractory gastrointestinal graft versus host disease
Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis